Brought to you by 
Merck licenses options on Vical's naked DNA technology.
16 Apr 2002
Executive Summary
Merck & Co. Inc. has exercised its remaining three options with Vical Inc. (polynucleotide and gene-based drugs) to license proprietary naked DNA vaccine technology to treat hepatitis B, herpes simplex and tuberculosis for $3 million.
Deal Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck licenses options on Vical's naked DNA technology.
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice